Paper Details

  1. Home
  2. Paper Details

Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.

Author: BoaF Y, De RaadtP, DiaiD, DouaF, HaegeleK D, KonianK, MiézanT W, SanonS R, SchechterP J, SjoerdsmaA

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Eflornithine, a polyamine biosynthesis inhibitor, was used to treat 14 patients with late-stage gambiense sleeping sickness, including 12 refractory to melarsoprol. Treatment resulted in rapid trypanosome disappearance from body fluids and decreased cerebrospinal fluid white blood cell counts.
Paper Details　
Original Abstract of the Article :
alpha-Difluoromethylornithine (DFMO; eflornithine), an inhibitor of polyamine biosynthesis, was used to treat 14 patients with late stage gambiense sleeping sickness, 12 cases having been previously treated with and considered refractory to melarsoprol. alpha-Difluoromethylornithine was administered...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4269/ajtmh.1987.37.525

データ提供：米国国立医学図書館（NLM）

Sleeping Sickness: A Desert Oasis for Research

Sleeping sickness, caused by the parasite Trypanosoma brucei, is a devastating disease affecting regions of Africa. This study investigates the efficacy and tolerability of alpha-difluoromethylornithine (DFMO; eflornithine), an inhibitor of polyamine biosynthesis, in treating late-stage gambiense sleeping sickness. Imagine researchers as explorers, venturing into the vast desert of sleeping sickness research to find new ways to combat this deadly disease. The study explores the potential of DFMO as a treatment option for patients who have not responded well to other therapies.

DFMO: A Beacon of Hope in the Desert

The study found that DFMO was effective in treating late-stage sleeping sickness, with a rapid disappearance of parasites from body fluids and a significant improvement in clinical signs and symptoms. DFMO also demonstrated the ability to penetrate the central nervous system, reaching therapeutic concentrations in the cerebrospinal fluid. This is like finding a hidden oasis in the desert, providing a much-needed source of relief for patients.

Hope on the Horizon: A New Oasis in the Desert of Sleeping Sickness

This research offers hope for individuals suffering from late-stage sleeping sickness. The study's findings highlight the potential of DFMO as an effective treatment option, providing a new oasis in the desert of sleeping sickness research. Further research is needed to fully understand the long-term effects of DFMO and to optimize its use in treating this debilitating disease.

Dr.Camel's Conclusion

The desert of sleeping sickness research is vast and challenging, but this study has uncovered a new oasis in the form of DFMO. This drug offers a promising treatment option for individuals suffering from late-stage sleeping sickness, providing hope for a brighter future in the fight against this devastating disease.

Date :
  1. Date Completed 1988-01-14
  2. Date Revised 2019-05-16
Further Info :

Pubmed ID

3120607

DOI: Digital Object Identifier

10.4269/ajtmh.1987.37.525

Related Literature

Article Analysis
・Side Effects of eflornithine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.